Harrison L B, Pfister D G, Kraus D, Armstrong J G, Zelefsky M J, Wiseberg J, Bosl G J, Strong E W, Shah J P
Skull Base Surg. 1994;4(3):127-31. doi: 10.1055/s-2008-1058963.
Between January 1988 and June 1992, 20 patients with unresectable malignant tumors at the skull base were treated. Eleven had T4 lesions of the paranasal sinus/cavity complex, and 9 had T4 nasopharynx cancer. All patients had stage IV disease by the American Joint Committee on Staging Criteria. The histology was squamous cell cancer in 15 patients and other minor salivary gland histologies in 5. There was brain and/or dural invasion in 11 patients and orbital invasion in 9. All patients received radiation therapy with accelerated fractionation to a total of 70 Gy in 6 weeks. Concomitant cisplatin (100 mg/m(2)) was given on days 1 and 22 of radiation. Seven patients received mitomycin C (7.5 mg/m(2)) on days 1 and 22, plus adjuvant chemotherapy with cisplatin and vinblastine. Median follow-up was 11 (range: 1 to 43) months. At 2 years, local progression-free survival was 94%, distant metastases-free survival was 57%, and overall survival was 80%. Complications occurred in 20% and caused the death of 1 patient. Treatment of this group of patients with aggressive chemotherapy and radiation therapy produced excellent local control in our early experience, but longer follow-up is needed. There is a high rate of distant failure. Future strategies are outlined.
1988年1月至1992年6月期间,对20例颅底不可切除恶性肿瘤患者进行了治疗。11例为鼻窦/鼻腔复合体T4期病变,9例为T4期鼻咽癌。根据美国联合委员会分期标准,所有患者均为IV期疾病。组织学类型为鳞状细胞癌15例,其他小涎腺组织学类型5例。11例患者有脑和/或硬脑膜侵犯,9例有眼眶侵犯。所有患者均接受加速分割放疗,6周内总量达70 Gy。放疗第1天和第22天给予顺铂(100 mg/m²)。7例患者在第1天和第22天接受丝裂霉素C(7.5 mg/m²),并加用顺铂和长春碱辅助化疗。中位随访时间为11个月(范围:1至43个月)。2年时,局部无进展生存率为94%,远处无转移生存率为57%,总生存率为80%。20%的患者出现并发症,1例患者死亡。在我们的早期经验中,对这组患者采用积极的化疗和放疗可产生良好的局部控制,但需要更长时间的随访。远处失败率较高。概述了未来的策略。